KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 105 filers reported holding KEROS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,264,054 | +9.1% | 71,018 | +37.5% | 0.00% | 0.0% |
| Q2 2023 | $2,075,659 | +72273.0% | 51,659 | -23.1% | 0.00% | 0.0% |
| Q1 2023 | $2,868 | -8.6% | 67,169 | +2.8% | 0.00% | 0.0% |
| Q4 2022 | $3,137 | -99.9% | 65,339 | +1.0% | 0.00% | 0.0% |
| Q3 2022 | $2,433,000 | +39.9% | 64,693 | +2.8% | 0.00% | 0.0% |
| Q2 2022 | $1,739,000 | -43.5% | 62,940 | +4.0% | 0.00% | 0.0% |
| Q1 2022 | $3,076,000 | +3.4% | 60,495 | -4.7% | 0.00% | 0.0% |
| Q4 2021 | $2,974,000 | +42.1% | 63,477 | -6.8% | 0.00% | 0.0% |
| Q3 2021 | $2,093,000 | -57.3% | 68,102 | -41.0% | 0.00% | 0.0% |
| Q2 2021 | $4,904,000 | -35.9% | 115,465 | -7.1% | 0.00% | -50.0% |
| Q1 2021 | $7,650,000 | +14.1% | 124,287 | +30.8% | 0.00% | 0.0% |
| Q4 2020 | $6,702,000 | +541.3% | 95,012 | +250.8% | 0.00% | – |
| Q3 2020 | $1,045,000 | +3.3% | 27,084 | +0.4% | 0.00% | – |
| Q2 2020 | $1,012,000 | – | 26,970 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 396,911 | $21,584,000 | 5.10% |
| Deep Track Capital, LP | 1,380,306 | $75,061,000 | 4.81% |
| Opaleye Management Inc. | 265,750 | $14,451,000 | 4.49% |
| Octagon Capital Advisors LP | 340,214 | $18,501,000 | 4.00% |
| First Light Asset Management, LLC | 658,145 | $35,790,000 | 3.16% |
| Altium Capital Management LP | 126,000 | $6,852,000 | 2.29% |
| Nantahala Capital Management | 816,830 | $44,419,000 | 1.96% |
| Orbimed Advisors | 1,679,417 | $91,327,000 | 1.48% |
| CHI Advisors LLC | 62,229 | $3,384,000 | 1.44% |
| Parkman Healthcare Partners LLC | 72,690 | $3,953,000 | 1.16% |